Vor Biopharma Stock (NASDAQ:VOR)

Forecast Ownership Financials Chart

Previous Close

$2.40

52W Range

$0.13 - $3.29

50D Avg

$0.56

200D Avg

$0.86

Market Cap

$317.40M

Avg Vol (3M)

$17.18M

Beta

-0.51

Div Yield

VOR Company Profile

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

159

IPO Date

Feb 05, 2021

Website

VOR Performance

VOR Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	$-121.19M	$-126.04M	$-93.42M
Net Income	$-116.91M	$-117.86M	$-90.77M
EBITDA	$-121.19M	$-114.37M	$-90.89M
Basic EPS	$-1.70	$-1.75	$-2.29
Diluted EPS	$-1.70	$-1.75	$-2.29

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

Ticker	Company
CCCC	C4 Therapeutics, Inc.
IMCR	Immunocore Holdings plc
DSGN	Design Therapeutics, Inc.
SANA	Sana Biotechnology, Inc.
CGEM	Cullinan Oncology, Inc.